# Tempest Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tempest-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.tempesttx.com
- Total disclosed funding: $40M
- Latest round: Series B (Feb 16, 2018)
- Investors on record: 6

## About

Tempest Therapeutics Inc. is a biotechnology company focused on developing innovative oral therapeutics targeting various cancer types, particularly through advanced immune-mediated therapies.Founded in 2011, Tempest Therapeutics Inc. operates from South San Francisco, US, specializing in cancer treatment solutions. The company underwent a reverse merger with Millendo Therapeutics, Inc. in March 2021. Tom Dubensky, the founder and CEO, leads the company, which has raised USD 15.00 mn in its most recent PIPE funding round on April 27, 2022, bringing the total amount raised to USD 15.00 mn across 6 deals.Tempest Therapeutics specializes in developing first-in-class oral drug therapeutics aimed at addressing various cancer types, with a focus on targeted and immune-mediated therapies. Their flagship product, Amezalpat (TPST-1120), is designed to treat patients with hepatocellular carcinoma and has received Orphan Drug Designation from the European Medicines Agency. The company serves oncologists and healthcare providers globally, leveraging advanced drug development techniques to create effective treatment options for cancer patients.In the most recent fiscal year of 2017, Tempest Therapeutics generated revenue of USD 295,000, with an EBITDA of -USD 41,637,000. The company primarily earns revenue through partnerships and collaborations, particularly surrounding Amezalpat, through licensing agreements and research collaborations with healthcare institutions and pharmaceutical partners.Tempest Therapeutics is focused on expanding its clinical pipeline and plans to launch new products aimed at enhancing its therapeutic offerings. The company targets an expansion into North American and European markets, utilizing recent funding of USD 15.00 mn to support these initiatives. The funds will facilitate the advancement of their primary product and the exploration of additional promising therapies, ensuring the company remains at the forefront of oncology treatment advancements.

## Funding rounds

- Series B, Feb 16, 2018, $25M — Versant Ventures, Eight Roads Ventures, F-Prime Capital, Lilly Asia Ventures, Foresite Capital, Quan Capital
- Series A, Dec 2, 2015, $15M — Lilly Asia Ventures

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series B